[Stock Market Briefing] Gene Therapy Stocks Strong Across the Board... SillaJen, Genexine, Appccell, and Toolgen Rise in Tandem

As the domestic stock market shows a strong rebound trend, bio stocks related to gene and cell-gene therapies are rising across the board, drawing market attention.

◆ Morning Session Fluctuation Rates of Major Gene Therapy Stocks During the morning session on the 9th, gene therapy-related stocks showed the following strength:

• Genexine: 3,085 KRW (up 8.63% from the previous trading day)
• ENCell: up 8.19%
• Appccell: up 8.16%
• Rgenomics: up 6.49%
• Helixmith: up 5.86%
• Toolgen: up 4.76%
• Curocell: up 4.21%

◆ Next-Generation Bio Technology Competition Begins in Earnest Recently, interest in next-generation gene therapies and gene editing technologies has been expanding within the bio industry. Gene therapies offer a differentiated approach from conventional drugs by correcting the disease-causing genes themselves or delivering therapeutic genes.

Looking at the notable areas for each company, Toolgen is standing out in the gene correction technology sector, while Appccell and Curocell are making their mark in the immune cell-based therapy sector. Additionally, Rgenomics is gaining attention in the RNA-based gene therapy platform sector, and Genexine, based on its next-generation bio new drug development capabilities, showed strength as it is mentioned as a related theme stock.

◆ Stock Market Rebound and Global Trends The strength of bio stocks on this day is interpreted as the result of improved investment sentiment following the successful rebound of the domestic stock market, which had plunged the previous day. In the KOSPI market, a strong buying influx occurred, enough to trigger a buy-side circuit breaker, and funds flowed into the bio industry, which has strong growth stock characteristics.

The market is paying attention to the possibility that the technological value of related companies will be reassessed as the competition for next-generation bio technologies intensifies, alongside the expansion of gene therapy investments by global pharmaceutical companies. In fact, the global bio market is seeing an expanding trend in the development competition for gene therapies, primarily focusing on rare diseases and cancer treatments.

◆ Investment Precautions However, due to the nature of the bio industry, stock price volatility can be significant depending on clinical trial results, technology exports, and licensing progress. Therefore, analysts suggest that investors need to carefully review the R&D achievements and business progress of individual companies.

[This article was written based on publicly available market data and official materials, and utilized artificial intelligence (AI) in the process of drafting the article and organizing the information. The information provided in this article is intended for general investment information purposes and does not constitute a solicitation to invest in specific stocks or financial products. Investing in the stock and financial markets carries the risk of principal loss, and all responsibility for investments lies with the investor. Please be sure to check related disclosures and official materials before making investment decisions. This publication does not bear any legal or financial responsibility for the information provided.]